Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,497
datasets available to search
ShareScore release 0.9.0
Dataset results
1,497 results for “Ischemic stroke”
Bibliography on COVID-19 and ischemic stroke
<p>Search on PubMed literature on COVID-19 and ischemic stroke.</p> <p>The uploaded database was generated on November 2, 2021. </p> <p>The database contains the following attributes:</p> <p>- PMID: PubMed identifier of the article. <br> - Autors: list of authors. <br> - Referència: bibliographic reference of the article. </p>
Data and Code for "Early complications after mild to moderate ischemic stroke and their impact on 3-months outcome: The prospective Stroke Unit Plus Cohort Study"
<p>This repository consists of the data and code for the publication "Early complications after mild to moderate ischemic stroke and their impact on 3-months outcome: The prospective Stroke Unit Plus Cohort Study"<br> <br> - Analysis code:<br> - Analysis.R<br> - Functions.R</p> <p>- Data:<br> - AnalysisSet in .Rdata, .csv, and .xlsx formats<br> <br> - Variable codebook in .xlsx format</p> <p>Responsibility for the upload lies with Prof. Jan Sobesky, e-mail: j.sobesky@ak-neuss.de<br> For inquiries regarding the data please contact Dr. Vince Madai, e-mail: vince_istvan.madai@bih-charite.de</p>
Fibrinogen depletion coagulopathy predicts major bleeding after thrombolysis for ischemic stroke: a multicentre study
<p>Dataset from "Fibrinogen depletion coagulopathy predicts major bleeding after thrombolysis for ischemic stroke: a multicentre study", Romoli & Vandelli et al., Stroke 2022</p>
Dataset related to article "ANTIHYPERTENSIVE DRUGS FOR SECONDARY PREVENTION AFTER ISCHEMIC STROKE OR TRANSIENT ISCHEMIC ATTACK"
<p>we performed a systematic review and meta-analysis in order to summarize the current evidence on blood pressure (BP)-lowering drugs for secondary prevention in patients with ischemic stroke or transient ischemic attack. We searched MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials up to January 31, 2020. We included randomized controlled trials comparing any specific BP-lowering drug, as monotherapy or combination, with either a control or another BP-lowering drug. Eight studies that enrolled 33 774 patients with ischemic stroke or transient ischemic attack were included in the meta-analysis. Primary outcomes were all-cause mortality and the proportion of patients who developed a stroke following BP-lowering drug use, irrespective of its nature (ischemic or hemorrhagic) and severity. Secondary outcomes included the proportion of patients who developed an ischemic stroke; an ischemic stroke or TIA irrespective of severity; a hemorrhagic stroke, defined as an acute extravasation of blood into and around the brain parenchyma (subdural hematoma and epidural hematoma were excluded); a cardiovascular event defined as any sudden death, fatal or nonfatal acute coronary syndrome, stroke, intracranial hemorrhage, or pulmonary embolism; a fatal cardiovascular event defined as any death due to any vascular cause, including unexplained sudden death; and serious adverse events of hypotension, syncope, injurious falls, electrolyte abnormalities, bradycardia, or acute renal failure. We recorded the outcomes at the longest available follow-up for all analyses. We considered the following potential sources of heterogeneity (effect modifiers): inclusion limited to hypertensive patients (normotensive and hypertensive patients versus hypertensive patients only) or noncardioembolic ischemic strokes (all ischemic strokes versus noncardioembolic ischemic strokes only), time from the index ischemic event to randomization (acute patients treated within the first week versus stabilized patients treated after the first week), and trial risk of bias.</p>
Dataset for: Effects of acute ischemic stroke on binaural perception, Dietze et al., Frontiers in Neurosciences, 2022
<p>This dataset contains the MNI-registered lesion masks of patients with strokes at different locations and the psychoacoustic results (tone in noise detection and lateralization) of stroke and control groups.<br> The dataset is described in Dietze A, Sörös P, Bröer M, Methner A, Pöntynen H, Sundermann B, Witt K and Dietz M (2022) Effects of acute ischemic stroke on binaural perception. Front. Neurosci. 16:1022354. doi: 10.3389/fnins.2022.1022354</p>
Dataset related to article "Harmonization of sensorimotor deficit assessment in a registered multicentre pre-clinical randomized controlled trial using two models of ischemic stroke"
<p>https://figshare.com/search?q=10.6084%2Fm9.figshare.21346731</p>
Predictive models for secondary Epilepsy in patients with acute Ischemic Stroke within one year
Open the record for dataset details and reuse information.
Diagnostic and prediction value of synthetic magnetic resonance imaging in acute ischemic stroke patients
<p>This is the supplementary tables for the above paper, mainly including original statistical analysis data.</p>
CPAISD: Core-Penumbra Acute Ischemic Stroke Dataset
<p>The dataset contains 112 non-contrast cranial CT scans of patients with hyperacute stroke, featuring delineated zones of penumbra and core of the stroke on each slice where present. The data in the dataset are anonymized using the Kitware DicomAnonymizer, with standard anonymization settings, except for preserving the values of the following fields:</p> <ul> <li>(0x0010, 0x0040) – Patient's Sex</li> <li>(0x0010, 0x1010) – Patient's Age</li> <li>(0x0008, 0x0070) – Manufacturer</li> <li>(0x0008, 0x1090) – Manufacturer’s Model Name</li> </ul> <p>The patient's sex and age are retained for demographic analysis of the samples, and the equipment manufacturer and model are kept for dataset statistics and the potential for domain shift analysis.</p> <p>The dataset is split into three folds:</p> <ul> <li>Training fold (92 studies, 8,376 slices).</li> <li>Validation fold (10 studies, 980 slices).</li> <li>Testing fold (10 studies, 809 slices).</li> </ul> <p>The dataset has the following structure:</p> <ul> <li>metadata.json – dataset metadata</li> <li>summary.csv – metadata of each study in a CSV format table</li> <li>Part of the dataset (train, val, and test) <ul> <li>Study <ul> <li>Slice <ul> <li>raw.dcm – original slice file</li> <li>image.npz – slice in Numpy array format</li> <li>mask.npz – segmentation mask in Numpy array format</li> <li>metadata.json – slice metadata in JSON format</li> </ul> </li> <li>metadata.json – study metadata in JSON format</li> </ul> </li> </ul> </li> </ul> <p>The metadata.json at the root of the dataset has the following format:</p> <ul> <li>generation_params – dataset generation parameters: <ul> <li>test_size – proportion of the test part</li> <li>val_size – proportion of the validation part</li> </ul> </li> <li>stats – statistical data: <ul> <li>common – general statistical data: <ul> <li>train_size_in_studies – number of studies in the training part of the dataset.</li> <li>train_size_in_images – number of slices in the training part of the dataset.</li> <li>val_size_in_studies – number of studies in the validation part of the dataset.</li> <li>val_size_in_images – number of slices in the validation part of the dataset.</li> <li>test_size_in_studies – number of studies in the test part of the dataset.</li> <li>test_size_in_images – number of slices in the test part of the dataset.</li> </ul> </li> <li>train – statistical data for the training part of the dataset: <ul> <li>min – minimum pixel value.</li> <li>max – maximum pixel value.</li> <li>mean – average pixel value.</li> <li>std – standard deviation for all pixel values.</li> </ul> </li> </ul> </li> </ul> <p>The metadata.json at the root of the study has the following format, if a field value is unknown, it is given as 'unknown':</p> <ul> <li>manufacturer – manufacturer of the tomograph.</li> <li>model – model of the tomograph.</li> <li>device – full name of the tomograph (manufacturer + model).</li> <li>age – patient's age in years.</li> <li>sex – patient's sex. M – male, F – female.</li> <li>dsa – whether cerebral angiography was performed. true if yes, false if no.</li> <li>nihss – NIHSS score.</li> <li>time – time in hours from the onset of the stroke to the conduct of the study. Can be either a number or a range.</li> <li>lethality – whether the person died as a result of this stroke. true if yes, false if no.</li> </ul> <p>The summary.csv contains the same fields as the `metadata.json` from the root of the study, plus two additional fields:</p> <ul> <li>name – name of the study.</li> <li>part – part of the dataset in which the study is located.</li> </ul>
Acute_ischemic_stroke_subregions_MCA
<p>This dataset contains information of 302 people with acute ischemic stroke within the territory of the middle cerebral artery. This information regards to age, sex, race, and predominance of the infarct in the frontal or temporoparietal areas.</p>
Association of Serum Biomarkers with Early Neurological Improvement after Intravenous Thrombolysis in Ischemic Stroke
<p><strong>Background:</strong> Early neurological improvement (ENI) after intravenous thrombolysis is associated with favorable outcome, but associated serum biomarkers were not fully determined. We aimed to investigate the issue in a prospective cohort.</p> <p><strong>Methods:</strong> In INTRECIS study, five centers were designed to consecutively collect the blood sample from enrolled patients. Enrolled patients with ENI and without ENI were matched by propensity score matching with the ratio of 1:1. Preset 49 biomarkers were measured through protein microarray analysis. Enrichment of Gene Ontology and pathway, and protein-protein interaction network were analyzed in the identified biomarkers.</p> <p><strong>Results:</strong> Of 358 patients, 19 occurred ENI, who were assigned as ENI group, while 19 matched patients without ENI were assigned as Non ENI group. A total of nine biomarkers were found different, among which levels of chemokine (C-C motif) ligand (CCL)-23, chemokine (C-X-C motif) ligand (CXCL)-12, insulin-like growth factor binding protein (IGFBP)-6, interleukin (IL)-5, lymphatic vessel endothelial hyaluronan receptor (LYVE)-1, plasminogen activator inhibitor (PAI)-1, platelet-derived growth factor (PDGF)-AA, suppression of tumorigenicity (ST)-2, and tumor necrosis factor (TNF)-α were higher in ENI group, compared with those in Non ENI group.</p> <p><strong>Conclusions:</strong> Our finding found that serum levels of CCL-23, CXCL-12, IGFBP-6, IL-5, LYVE-1, PAI-1, PDGF-AA, ST-2, and TNF-α at admission were associated with post-thrombolytic ENI in ischemic stroke. The role of these biomarkers warrant further investigation.</p>
Functional Polymorphism in miR-208 Is Associated with Increased Risk for Ischemic Stroke
<p>根据对基因型、模型和等位基因的分析,观察到rs8022522多态性与IS风险之间存在显著相关性(GA与GG:校正OR=2.159,95%CI:1.052-4.430,<em>P</em> = 0. 036;AA 与 GG:调整后 OR = 5.154,95% CI:1.123-23.660,<em>P</em> = 0.035;显性模型:校正OR=1.746,95%CI,1.075-2.838,<em>P</em> = 0.025;G 与 A:调整后 OR = 2.451,95% CI:1.374-4.370)。</p>
A multi-laboratory preclinical trial to assess treatment candidates for acute ischemic stroke
<p>Human diseases may be modeled in animals to allow preclinical assessment of putative new clinical interventions. Recent, highly publicized failures of large clinical trials called into question the rigor, design, and value of preclinical assessment. We established the Stroke Preclinical Assessment Network (SPAN) to design and implement a randomized, controlled, blinded, multi-laboratory network for the rigorous assessment of candidate stroke treatments combined with intravascular thrombectomy. Futility boundaries in a Multi-Arm Multi-Stage statistical design aimed to exclude less effective interventions, and efficacy boundaries allowed early declaration of success after each of four sequential stages. Six independent research laboratories performed a standard focal cerebral ischemic insult in five animal models that included equal numbers of males and females: young mice, young rats, aging mice, mice with diet-induced obesity, and spontaneously hypertensive rats. The laboratories adhered to a common protocol and efficiently enrolled 2,615 animals with full data completion and comprehensive animal tracking. SPAN successfully implemented treatment masking, randomization, pre-randomization inclusion and exclusion criteria, and blinded assessment of outcomes. <a>The</a> SPAN design and infrastructure provide an effective approach that could be used in similar preclinical, multi-laboratory studies in other disease areas, and should help improve reproducibility in translational science.</p>
Which Parameters of Short-term Blood Pressure Variability Best Predict Early Outcomes in Acute Ischemic Stroke
ClinicalTrials.gov study NCT02675972. IPD Sharing: NO. Countries: 1. Publications: 1.
Safety and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic Stroke
ClinicalTrials.gov study NCT00821821. IPD Sharing: Not stated. Countries: 3. Publications: 1.
SEdation Versus General Anesthesia for Endovascular Therapy in Acute Ischemic Stroke
ClinicalTrials.gov study NCT03263117. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Vertebrobasilar Flow Evaluation and Risk of Transient Ischemic Attack and Stroke (VERiTAS)
ClinicalTrials.gov study NCT00590980. IPD Sharing: Not stated. Countries: 2. Publications: 8.
Systematic Evaluation of Patients Treated With Stroke Devices for Acute Ischemic Stroke (STRATIS) Registry
ClinicalTrials.gov study NCT02239640. IPD Sharing: NO. Countries: 1. Publications: 8.
Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke (CLEAR-FDR)
ClinicalTrials.gov study NCT01977456. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
ClinicalTrials.gov study NCT02586415. IPD Sharing: Not stated. Countries: 1. Publications: 19.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.